Investigating how a virus linked to skin cancer affects tumor growth
Official title: Targeting MCPyV oncogene transcription to suppress tumorigenesis
Funded at University of Pennsylvania · NIH-10880633 · Data updated 2026-11-12
This study is looking into how a virus called Merkel cell polyomavirus might help cause a type of skin cancer called Merkel cell carcinoma, especially in people with weakened immune systems, like those with HIV, to find new ways to treat this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 3, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $353,134 |
| NIH project number | 5R01CA284690-02 |
| Project ID | NIH-10880633 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with Merkel cell carcinoma, particularly those who are immunocompromised.
✕Less likely to help
Patients without Merkel cell carcinoma or those who are not immunocompromised may not benefit from this research.
What this research studies
This research focuses on understanding how the Merkel cell polyomavirus (MCPyV) contributes to the development of Merkel cell carcinoma (MCC), a serious skin cancer. The study aims to uncover the mechanisms by which MCPyV promotes tumor growth, particularly in individuals with weakened immune systems, such as those living with HIV. By exploring the virus's life cycle and its interaction with host cells, the research seeks to identify potential targets for new treatments. Patients may benefit from insights that could lead to more effective therapies for MCC.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with Merkel cell carcinoma.
How similar studies have gone: Other research has shown promise in understanding viral mechanisms in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: You, Jianxin — University of Pennsylvania
- Study coordinator: You, Jianxin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.